Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide and in China. Screening for lung cancer by low dose computed tomography (LDCT) can reduce mortality but has resulted in a dramatic rise in the incidence of indeterminate pulmonary nodules, which presents a major diagnostic challenge for clinicians regarding their underlying pathology and can lead to overdiagnosis. To address the significant gap in evaluating pulmonary nodules, we conducted a prospective study to develop a prediction model for individuals at intermediate to high risk of developing lung cancer. Univariate and multivariate logistic analyses were applied to the training cohort (n = 560) to develop an early lung cancer prediction model. The results indicated that a model integrating clinical characteristics (age and smoking history), radiological characteristics of pulmonary nodules (nodule diameter, nodule count, upper lobe location, malignant sign at the nodule edge, subsolid status), artificial intelligence analysis of LDCT data, and liquid biopsy achieved the best diagnostic performance in the training cohort (sensitivity 89.53%, specificity 81.31%, area under the curve [AUC] = 0.880). In the independent validation cohort (n = 168), this model had an AUC of 0.895, which was greater than that of the Mayo Clinic Model (AUC = 0.772) and Veterans’ Affairs Model (AUC = 0.740). These results were significantly better for predicting the presence of cancer than radiological features and artificial intelligence risk scores alone. Applying this classifier prospectively may lead to improved early lung cancer diagnosis and early treatment for patients with malignant nodules while sparing patients with benign entities from unnecessary and potentially harmful surgery.Clinical Trial Registration NumberChiCTR1900026233, URL: http://www.chictr.org.cn/showproj.aspx?proj=43370.

Highlights

  • 22% of the newly diagnosed cancer cases worldwide and 27% of cancer-related deaths occur in China [1]

  • We evaluated the diagnostic ability of the AI risk score and liquid biopsy results to discriminate between benign and malignant nodules

  • Weak internal validity between the AI risk score and liquid biopsy data (k = 0.16, 95% CI: 0.072–0.247) was observed, indicating the good complementary value of the two tools in early lung cancer diagnosis

Read more

Summary

Introduction

22% of the newly diagnosed cancer cases worldwide and 27% of cancer-related deaths occur in China [1]. Based on the results of the National Lung Screening Trial (NLST) [3, 4], low-dose computed tomography (LDCT) is the recommended test for lung cancer screening, but the high false-positive rate has diminished the benefits of the test; in a previous study, only 3.6% of the participants who had pulmonary nodules were confirmed to have lung cancer [3]. Clinicians use diagnostic decision tools to stratify the malignancy risk of patients with positive LDCT results [5]. The Mayo Clinic Model has been extensively validated worldwide and includes factors such as age, smoking history, extra-thoracic cancer history, spiculation, nodule diameter, and upper lobe location [6]. The diagnostic significance of the malignant risk factor “upper lobe location” is weakened owing to the high prevalence of tuberculosis [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call